688192 Dizal
- 43.48
- +1.00+2.35%
Dizal News
Dizhe Pharmaceutical (688192): The first year of commercialization has begun
Incident: Recently, the company released its 2023 annual report. In 2023, the company achieved operating income of 91.2886 million yuan, net profit attributable to shareholders of listed companies - RMB 1,108 billion, and deductions attributable to shareholders of listed companies
Downgrade: Here's How Analysts See Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Performing In The Near Term
The latest analyst coverage could presage a bad day for Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192), with the analysts making across-the-board cuts to their statutory estimates that might l
Dizhe Pharmaceutical (688192.SH): Chairman and others completed an increase in holdings of 6.59 million yuan
Dizhe Pharmaceutical (688192.SH) announced that as of May 8, 2024, Dr. Zhang Xiaolin, Chairman and CEO of the company, Mr. Lu Hongbin, Secretary of the Board of Directors and Chief Financial Officer, and Ms. Wu Qingyi, Deputy General Manager and Chief Commercial Officer, have increased their holdings by 1991.88 million shares, accounting for 0.0479% of the company's total share capital, with a total increase of 6.597.42 million yuan. The implementation of this increase plan has been completed.
Digel Pharmaceuticals (688192): Fast dosage of suvortinib is optimistic about innovative catalysis
2023&2024Q1 rapid release of suvortinib, acceleration of company pipeline implementation, 2024ASCO will soon announce second-line treatment of EGFR exon20ins mutant advanced NSCLC MRC with sulvortinib
Dizhe Pharmaceutical (688192): Revenue is in line with expectations, core products are progressing in an orderly manner worldwide
The 2023 and 1Q24 results are in line with our expectations. The company announced the 2023 and 1Q24 results: 2023 revenue of 91.289 million yuan, net profit to mother of 1.11 billion yuan, in line with our expectations. incorporation
These 4 Measures Indicate That Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Express News | Dizhe Pharmaceutical: Schwarzhe's performance exceeded expectations and accelerated commercialization
Dizhe Pharmaceutical (688192.SH) announced its 2023 annual results with a net loss of 1.08 billion yuan
Dizhe Pharmaceutical (688192.SH) released its 2023 annual performance report. During the reporting period, the company achieved an operating income of 9...
2024 CSCO guide major update! Schwarzhe was included in the Level I recommendation, and goliximitinib was recommended for the first time, breaking through the bottleneck of treating difficult tumor targets
SHANGHAI, April 27, 2024/PRNewswire/ -- From April 26 to 27, 2024, the Chinese Society of Clinical Oncology (CSCO) guidelines conference was held in Jinan. In the 2024 CSCO diagnosis and treatment guidelines released at this conference, the two original innovative drugs independently developed by Dizhe Pharmaceutical (stock code: 688192.SH), and golisitinib, were both included in the guidelines as recommended drugs. Schwarzhe was recommended by the “CSCO Guidelines for the Diagnosis and Treatment of Non-small Cell Lung Cancer (2024 Edition)” at Level I, which targets experience in this guideline
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological...
FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as
Digger Pharmaceutical's advanced EGFR Ex20ins mutation frontline was once again recognized as a breakthrough therapy by the FDA, and the global registered clinical study was selected for the 2024 ASCO oral report
SHANGHAI, April 7, 2024/PRNewswire/ -- On April 7, 2024, Dizhe Pharmaceutical (stock code: 688192.SH) announced that the US Food and Drug Administration (FDA) granted breakthrough therapy certification for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 (exon20ins) mutations. This is a follow-up to the advanced NSCL mutant of EGFR exon20ins
Dizhe Pharmaceutical (688192): Optimistic about global innovation from a high starting point
Key investment points Digitzer Pharmaceuticals was born out of the former AstraZeneca R&D center in Asia. It is a local new pharmaceutical company with a high starting point to build a differentiated pipeline. We are optimistic about the company's core pipeline differentiation and international competitive advantage. The company's core product Suvortinib has indications from the second tier
Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s (SHSE:688192) Largest Shareholders Are Private Equity Firms Who Were Rewarded as Market Cap Surged CN¥1.4b Last Week
Key Insights Significant control over Dizal (Jiangsu) Pharmaceutical by private equity firms implies that the general public has more power to influence management and governance-related decisions A
Digel Pharmaceutical (688192.SH) Performance Report: Net loss of 1,123 billion yuan in 2023
Gelonghui, Feb. 23 | Digi Pharmaceutical (688192.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total operating income of 91.2886 million yuan; net profit attributable to owners of the parent company - 1,123 million yuan; net profit attributable to owners of the parent company after deducting non-recurring profit and loss - 1,177 million yuan; basic earnings per share - 2.75 yuan
The chairman of Dizhe Pharmaceutical (688192.SH) increased his total holdings by 161,000 shares
Dizhe Pharmaceutical (688192.SH) issued an announcement. As of February 18, 2024, the company's chairman and chief...
Express News | Today's Dizhe Pharmaceutical-U bulk transaction was 72.418,700 yuan, with a premium rate of 3.46%
Express News | More than 30 listed companies announced plans to repurchase or increase their holdings after the market. SF Holdings and Haitong Securities plan to repurchase shares of up to 1 billion yuan and 600 million yuan respectively
Dizhe Pharmaceutical (688192.SH) forecasted losses and is expected to lose a huge loss of about 1,119 billion yuan in 2023
Dizhe Pharmaceutical (688192.SH) released its 2023 annual results forecast and is expected to operate in 2023...
Express News | Dizhe Pharmaceutical: Directors and senior management plan to increase their holdings of the company by 6.5 million yuan to 13 million yuan
Analysis
Price Target
No Data
